Ian has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and a member of the board of directors for Genentech, a member of the Roche Group, until his retirement in 2016. During his seven-year tenure as CEO, Ian and his team brought 11 new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Ian was among the highest rated CEOs by Glassdoor, recognized as the Bay Area’s most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Healthcare Businesswomen’s Association. Prior to joining Genentech, Ian held various positions of increasing responsibility at Novartis, Sano, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France.
Currently, Ian is on the board of directors of Takeda, Agios Pharmaceuticals, Guardant Health and Corvus Pharmaceuticals, and serves as chairman of the board of Olema Oncology. He is an operating partner of Blackstone Life Sciences and a member of the BioFulcrum Board of the Gladstone Institutes. Ian previously served on the boards of Shire, Kite Pharma, Dendreon, Solazyme, Forty Seven and Vernalis. He was also on the board of Biotechnology Industry Association and on the Economic Advisory Council of the 12th District of the Federal Reserve.
Ian received his BS in biological sciences and an honorary DSc from Southampton University in the United Kingdom.